 CAMBRIDGE, Mass., Sept. 16, 2021 GLOBE NEWSWIRE -- Spero Therapeutics, Inc. Nasdaq: SPRO, a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America IDSA IDWeekTM 2021, taking place virtually from September 29 October 3, 2021. Presentations will showcase in vitro and in vivo studies of Speros oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection cUTI and acute pyelonephritis AP and highlight additional research on the epidemiology and management of cUTI. 